All the attention is on aducanumab, but yesterday’s deal with Denali is a reminder that Biogen has other irons in the fire.
Upcoming US approval verdicts include inclisiran, valrox and risdiplam, but toxicity issues could scupper filgotinib.
The CS1 approach to treating multiple myeloma was once thought capable of matching CD38, but that train left the station some time ago.
Incyte hands across $750m up front and buys $150m of Morphosys equity for rights to the anti-CD19 project.
On the corporate front Astellas continued to buy, while Qiagen decided that it was not, after all, up for sale.
The anti-CD19 MAb is Morphosys’s lead pipeline asset, and an imminent filing could see it approved next year.